Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Preferred Stock Liabilities (2016 - 2025)

Enanta Pharmaceuticals filings provide 13 years of Preferred Stock Liabilities readings, the most recent being $1.3 million for Q4 2025.

  • On a quarterly basis, Preferred Stock Liabilities fell 2.89% to $1.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.3 million, a 2.89% decrease, with the full-year FY2025 number at $1.3 million, down 2.89% from a year prior.
  • Preferred Stock Liabilities hit $1.3 million in Q4 2025 for Enanta Pharmaceuticals, roughly flat from $1.3 million in the prior quarter.
  • In the past five years, Preferred Stock Liabilities ranged from a high of $1.5 million in Q3 2021 to a low of $1.3 million in Q3 2025.
  • Median Preferred Stock Liabilities over the past 5 years was $1.4 million (2022), compared with a mean of $1.4 million.
  • The widest YoY moves for Preferred Stock Liabilities: up 1.83% in 2021, down 9.15% in 2021.
  • Enanta Pharmaceuticals' Preferred Stock Liabilities stood at $1.5 million in 2021, then decreased by 5.51% to $1.4 million in 2022, then changed by 0.0% to $1.4 million in 2023, then dropped by 5.13% to $1.3 million in 2024, then fell by 2.89% to $1.3 million in 2025.
  • The last three reported values for Preferred Stock Liabilities were $1.3 million (Q4 2025), $1.3 million (Q3 2025), and $1.3 million (Q2 2025) per Business Quant data.